Stocksigma LogoStocksigma Logo

Aptus Pharma Receives In-Principle BSE Approval for Preferential Issue

Aptus Pharma Ltd. received in-principle approval from BSE Ltd. on 30th Oct'26 under Regulation 28(1) of SEBI LODR Regulations for a proposed preferential

Aptus Pharma Receives In-Principle BSE Approval for Preferential Issue

Aptus Pharma Ltd 路 Others (Uncategorized) 路 31 Oct 2026, 1:01 am

Aptus Pharma Receives In-Principle BSE Approval for Preferential Issue Aptus Pharma Ltd. received in-principle approval from BSE Ltd. on 30th Oct'26 under Regulation 28(1) of SEBI LODR Regulations for a proposed preferential issue. The approval covers the issuance of 15,99,270 equity shares (face value of Rs. 10 each) at a minimum price of Rs. 280 per share to promoters and non-promoters, aggregating to at least Rs. 44.78 cr. The issue was previously approved by shareholders at the AGM on 14th Sep'26. Final listing remains subject to regulatory compliance and post-allotment filings.

Original exchange filing (PDF)

More announcements from Aptus Pharma Ltd

All Aptus Pharma Ltd announcements